Clinical significance of high monocyte counts for the continuous treatment with nintedanib.
Adverse events
Monocyte count
Nintedanib
Starting dosage
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
received:
03
02
2023
accepted:
27
06
2023
medline:
5
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Nintedanib is now widely used to treat interstitial lung disease (ILD). Adverse events, which occur in not a few patients, make it difficult to continue nintedanib treatment, but the risk factors for adverse events are not well understood. In this retrospective cohort study, we enrolled 111 patients with ILDs treated with nintedanib and investigated the factors involved in starting dosage reduction, withdrawal, or discontinuation within 12 months, even with appropriate symptomatic treatment. We also examined the efficacy of nintedanib in reducing the frequency of acute exacerbations and the prevention of pulmonary function reduction. Patients with high monocyte counts (> 0.454 × 10 Our study results indicate that patients with higher monocyte counts (> 0.454 × 109/L) should very careful about side effects with regard to nintedanib administration. Like BSA, a higher monocyte count is considered a risk factor for nintedanib treatment failure. There was no difference in FVC decline and frequency of acute exacerbations between the starting doseage of nintedanib, 300 mg and 200 mg. Considering the risk of withdrawal periods and discontinuation, a reduced starting dosage may be acceptable in the patients with higher monocyte counts or small body sizes.
Sections du résumé
BACKGROUND
BACKGROUND
Nintedanib is now widely used to treat interstitial lung disease (ILD). Adverse events, which occur in not a few patients, make it difficult to continue nintedanib treatment, but the risk factors for adverse events are not well understood.
METHODS
METHODS
In this retrospective cohort study, we enrolled 111 patients with ILDs treated with nintedanib and investigated the factors involved in starting dosage reduction, withdrawal, or discontinuation within 12 months, even with appropriate symptomatic treatment. We also examined the efficacy of nintedanib in reducing the frequency of acute exacerbations and the prevention of pulmonary function reduction.
RESULTS
RESULTS
Patients with high monocyte counts (> 0.454 × 10
CONCLUSION
CONCLUSIONS
Our study results indicate that patients with higher monocyte counts (> 0.454 × 109/L) should very careful about side effects with regard to nintedanib administration. Like BSA, a higher monocyte count is considered a risk factor for nintedanib treatment failure. There was no difference in FVC decline and frequency of acute exacerbations between the starting doseage of nintedanib, 300 mg and 200 mg. Considering the risk of withdrawal periods and discontinuation, a reduced starting dosage may be acceptable in the patients with higher monocyte counts or small body sizes.
Identifiants
pubmed: 37400801
doi: 10.1186/s12890-023-02536-y
pii: 10.1186/s12890-023-02536-y
pmc: PMC10318667
doi:
Substances chimiques
nintedanib
G6HRD2P839
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
242Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2017 Sep 7;7(1):10811
pubmed: 28883482
Respir Investig. 2021 Jan;59(1):99-105
pubmed: 32891571
Radiology. 2004 Aug;232(2):560-7
pubmed: 15286324
Am J Respir Crit Care Med. 2021 Jul 1;204(1):74-81
pubmed: 33434107
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
Sci Rep. 2020 Jul 16;10(1):12080
pubmed: 32669649
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Respir Res. 2021 May 5;22(1):140
pubmed: 33952261
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):74-78
pubmed: 32476938
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Adv Ther. 2021 Feb;38(2):854-867
pubmed: 33315170
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Chron Respir Dis. 2020 Jan-Dec;17:1479973120909840
pubmed: 32141310
Lancet Respir Med. 2019 Jan;7(1):60-68
pubmed: 30224318
Thorax. 2018 Jun;73(6):581-583
pubmed: 28993537
Eur Respir J. 2021 Jul 8;58(1):
pubmed: 33678609
Respir Investig. 2019 May;57(3):282-285
pubmed: 30772264
Lancet Respir Med. 2019 Jun;7(6):497-508
pubmed: 30935881
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Pulm Pharmacol Ther. 2020 Jun;62:101917
pubmed: 32205281